Regional Variation on Rates of Bronchopulmonary Dysplasia and Associated Risk Factors by Rojas, Maria Ximena et al.
Florida International University
FIU Digital Commons
All Faculty
5-9-2012
Regional Variation on Rates of Bronchopulmonary
Dysplasia and Associated Risk Factors
Maria Ximena Rojas
Pontificia Universidad Javeriana
Mario Augusto Rojas
Wake Forest University
Juan Manuel Lozano
Herbert Werthiem College of Medicine, Florida International University, jlozanol@fiu.edu
Martin Alonso Rondon
Pontificia Universidad Javeriana
Laura Patricia Charry
Pontificia Universidad Javeriana
Follow this and additional works at: https://digitalcommons.fiu.edu/all_faculty
This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in All Faculty by an authorized
administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Recommended Citation
Rojas, Maria Ximena; Rojas, Mario Augusto; Lozano, Juan Manuel; Rondon, Martin Alonso; and Charry, Laura Patricia, "Regional
Variation on Rates of Bronchopulmonary Dysplasia and Associated Risk Factors" (2012). All Faculty. 26.
https://digitalcommons.fiu.edu/all_faculty/26
International Scholarly Research Network
ISRN Pediatrics
Volume 2012, Article ID 685151, 9 pages
doi:10.5402/2012/685151
Research Article
Regional Variation on Rates of Bronchopulmonary Dysplasia and
Associated Risk Factors
Marı´a Ximena Rojas,1 Mario Augusto Rojas,2 JuanManuel Lozano,3
Martı´n Alonso Rondo´n,1 and Laura Patricia Charry1
1Department of Clinical Epidemiology and Biostatistics, School of Medicine, Pontificia Universidad Javeriana,
Bogota´ 110001, D.C., Colombia
2Division of Neonatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
3Division of Research and Information, College of Medicine, Florida International University, Miami, FL, USA
Correspondence should be addressed to Marı´a Ximena Rojas, mxrojas@javeriana.edu.co
Received 6 March 2012; Accepted 9 May 2012
Academic Editors: G. J. Casimir, D. L. Jeppesen, S. K. Patole, and T. F. Yeh
Copyright © 2012 Marı´a Ximena Rojas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. An abnormally high incidence (44%) of bronchopulmonary dysplasia with variations in rates among cities was
observed in Colombia among premature infants. Objective. To identify risk factors that could explain the observed high incidence
and regional variations of bronchopulmonary dysplasia. Study Design. A case-control study was designed for testing the hypothesis
that diﬀerences in the disease rates were not explained by diﬀerences in city-of-birth specific population characteristics or by
diﬀerences in respiratory management practices in the first 7 days of life, among cities. Results. Multivariate analysis showed that
premature rupture of membranes, exposure to mechanical ventilation after received nasal CPAP, no surfactant exposure, use of
rescue surfactant (instead of early surfactant), PDA, sepsis and the median daily FIO2, were associated with a higher risk of dyspla-
sia. Significant diﬀerences between cases and controls were found among cities. Models exploring for associations between city of
birth and dysplasia showed that being born in the highest altitude city (Bogota´) was associated with a higher risk of dysplasia
(OR 1.82 95% CI 1.31–2.53). Conclusions. Bronchopulmonary dysplasia was manly explained by traditional risk factors. Findings
suggest that altitudemay play an important role in the development of this disease. Prenatal steroids did not appear to be protective
at high altitude.
1. Introduction
Despite all the advances in the care of premature infants
with respiratory distress syndrome (RDS), including the use
of antenatal steroids and early management with surfactant,
bronchopulmonary dysplasia (BPD) continues to be a major
cause of chronic morbidity among this population. There
are large variations in the incidence and severity of this
disease. According to the National Institutes of Health of
USA (NICHD) consensus [1], mild BPD is defined as a need
for supplemental oxygen for ≥28 days at 36 weeks post-
menstrual age (wPMA) or discharge, moderate BPD as sup-
plemental oxygen for ≥28 days plus treatment with <30%
oxygen at 36wPMA, and severe BPD as supplemental oxygen
for ≥28 days plus ≥30% oxygen and/or positive pressure
at 36wPMA. Currently, the estimated incidence of BPD
defined as need for supplemental oxygen at 36wPMA in the
United States is approximately 30% for premature infants
with a birth weight <1000 grams and <7% in infants with
a birth weight >1250 grams or who were at least 30 weeks of
gestation at birth [1, 2].
Previous epidemiological studies have identified prema-
turity, oxygen toxicity, and mechanical ventilation as major
risk factors associated with BPD [3–7]. Additional risk fac-
tors include perinatal or postnatal infection/inflammation
[8–12], pulmonary edema resulting from patent ductus
arteriosus (PDA) [12, 13] or excess fluid administration [7,
14, 15], vitamin A deficiency [16], early adrenal insuﬃciency
[17], and, more recently, genetic polymorphism [18].
There is little information about trends in the epidemi-
ology and pathogenesis of BPD in developing countries.
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The most recent report of the incidence of BPD in Latin
America comes from theNEOCOSURNeonatal Group study
in 1,825 very-low-birth-weight (VLBW) infants born in
sixteen hospitals from Argentina, Chile, Paraguay, Peru, and
Uruguay [19]. The authors found an incidence of BPD (oxy-
gen requirement at 28 days of life with chronic radiographic
changes) of 24.4%. A randomized controlled trial of early
bubble nasal continuous positive airway pressure (nCPAP)
and surfactant in premature infants conducted in three
diﬀerent cities in Colombia [20] found an incidence of BPD
(defined as supplemental oxygen requirement at 36wPMA)
twice as large (44%) as the one observed in less mature
premature infants in developed countries or in the NEO-
COSUR study. The Colombian trial also revealed significant
variations in BPD rates among participating cities: Bogota´
50%, Cali 18%, and Bucaramanga 13%. These cities have
diﬀerent characteristics, the most important being altitude:
Bogota´ is 2600 meters above sea level (masl), Bucaramanga
959masl, and Cali 956masl.
We conducted this study with the aim of identifying
environmental, maternal, infant, and therapeutic risk factors
associated with BPD in Colombia. We also tested the hypo-
thesis that diﬀerences in BPD rates were not explained by dif-
ferences in city-of-birth-specific population characteristics
or by diﬀerences in respiratory management practices during
the first seven days of infants’ life among cities.
2. Materials/Subjects andMethods
This is a nested case-control study based on data collected
as part of a multicenter randomized controlled trial carried
out by the Colombian Neonatal Research Network in eight
neonatal intensive care units (NICUs) located in three cities
(Bogota´, Bucaramanga, and Cali) in Colombia. A detailed
description of this trial has been published [20]. Briefly,
premature infants born between 27 and 31 weeks of gestation
with clinical evidence of respiratory distress during the first
hour of life, and who did not require intubation as part of
their initial resuscitation and stabilization, were placed on
bubble nCPAP and then randomized to receive very early
surfactant therapy through transient intubation followed by
nCPAP or to expectant management on nCPAP alone. A total
of 279 premature infants were enrolled in the trial from Jan-
uary 1, 2004 to December 31, 2006. All study sites provided
comprehensive continuous care for critically ill neonates and
were staﬀed by trained nurses and specialized physicians
with fully equipped and modern neonatal units. Prenatal
and neonatal data were collected prospectively until death or
discharge. Additional data were collected at 36wPMA.
The neonatal survival for the population included in
the RCT was 90.7%. Neonatal mortality rates were similar
among cities. For the present study, all analyses were limited
to infants who survived to 36wPMA. Bronchopulmonary
dysplasia was defined as the need for supplemental oxygen
for ≥28 days at 36wPMA [1]. The target oxygen arterial sat-
uration (SaO2) was 92% for infants treated in Bogota and
96% for those treated in other cities. Given the high altitude
in Bogota´ it was expected that SaO2 would be lower than in
infants at lower altitudes [21, 22]. Neonates who fell under
this definition were considered as cases. Since we used an
epidemiological definition for BPD and we did not have
the radiographic findings to confirm BPD cases, to avoid
misclassification bias “controls” were all infants who were
not receiving supplemental oxygen at 36wPMA and had
required <20 days of oxygen supplementation or had not
required oxygen supplementation at all. Cases and controls
were compared to identify risk factors associated with
BPD. Relevant exposure data included maternal and infant
perinatal characteristics, infant postnatal diagnosis, and res-
piratory management practices. Preterm premature rupture
of membranes (PPROM) was defined as >12 hours, use of
antenatal steroids as the administration of a complete course
(two 12mg intramuscular doses of betamethasone within 24
hours) of maternal steroids at least 24 hours before delivery,
confirmed chorioamnionitis as a positive amniotic fluid cul-
ture, and suspected chorioamnionitis as maternal fever during
labor and fetal tachycardia. Gestational age (GA) at birth was
estimated using the last menstrual period date; when GA was
inconsistent with the physical examination, the Ballard score
was used [23]. Small for gestational age (SGA) was defined as
a birth weight <10th percentile for age [24]. PDA was con-
firmed by echocardiography and subsequently treated with
indomethacin or surgical ligation. Sepsis was defined as a
clinical deterioration with temperature instability, recurrent
apnea, and at least one of the following indications of altered
organ function: lethargy, hypoxemia, and increased serum
lactate level [25]. Grades III and IV IVH were identified by
head ultrasound using the Papile et al. criteria [26]. Air leak
syndrome included radiological evidence of pneumothorax,
pneumomediastinum, or pulmonary interstitial emphysema.
The Score for Neonatal Acute Physiology (SNAP II) on the
day of admission was calculated from clinical data collected
prospectively during the first day of life [27]. Respiratory
management variables included type of ventilatory support
received: (a) only nCPAPwhen infants were placed on nCPAP
without subsequent mechanical ventilation (MV) during
their NICU stay, (b) nCPAP + MV when infants on nCPAP
met treatment failure criteria and requiredMV. Length of MV
was categorized in ≥7 days or <7 days. Exposure to surfactant
was divided into three categories: (a) no surfactant exposure
included all infants who did not receive surfactant during the
trial, (b) very early surfactant included infants administered
surfactant within the first hour of life, and (c) rescue sur-
factant included infants administered surfactant after the
first hour of life. Exposure to oxygen supplementation was
measured by fraction of inspired oxygen (FIO2) registered
daily.
Demographic and clinical characteristics of the study
population were summarized. To identify diﬀerences in the
distribution of studied variables between cases and controls,
the statistical analysis included hypothesis testing using the
Pearson Chi-square test for categorical variables and the Stu-
dents t-test for continuous variables. To explore associations
between studied variables and BPD, crude and adjusted odds
ratios (ORs) with 95% confidence intervals (95% CIs) were
estimated in a bivariate analysis, followed by a multivariate
regression analysis using a log-binomial generalized linear
model that included all significant variables in a manual
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Table 1: Demographic characteristics of population studied by cases and controls.
All infants
BPD
Cases Controls
P
n = 212 n = 64 n = 148
Maternal age, y, mean± (SD) 27.2 (6.5) 26.1 (6.0) 27.3 (6.6) 0.205
Male (%) 108 (50.9) 34 (53.1) 74 (50.0) 0.676
Gestational age at birth, wPMA, mean± (SD) 29.2 (1.3) 28.6 (1.2) 29.3 (1.3) 0.001
Birth weight, grams, mean± (SD) 1271.2 (283.3) 1155.3 (263.0) 1306.5 (284.2) 0.000
SGA, n (%) 12 (5.7) 3 (4.7) 9 (6.1) 0.688
APGAR score 5min, median (IR) 9 (8-9) 9 (8-9) 9 (8-9) 0.228
SNAP-II, score, mean± (SD) 5.7 (9) 7.6 (10.5) 5.4 (8.6) 0.102
BPD: bronchopulmonary dysplasia, wPMA: weeks postmenstrual age, SGA: small for gestational age, SNAP-II: score for neonatal acute physiology, SD:
standard deviation, IR: Interquartile range (diﬀerence between the value at 75% of cases, and the value at 25% of cases).
forward stepwise approach. The Wilcoxon rank sum test was
used to compare the median values between groups and the
Generalized Cochrane Mantel-Haenszel test to assess the
statistical significance of associations between categorical
variables.
To determine diﬀerences in population characteristics or
in respiratory management variables during the first week of
life that could explain the diﬀerences in BPD rates among
cities, a descriptive analysis of selected variables was per-
formed by city of birth, followed by a bivariate analysis to
identify variables mainly associated with BPD in each city.
To identify possible diﬀerences in the distribution of studied
variables between three cities among cases of BDP, the statis-
tical analysis included hypothesis testing using the Pearson
Chi-square test for categorical variables and the Analysis
of Variance or Kruskall Wallis test for continuous variables.
Multivariate analyses were then conducted to explore asso-
ciations between city of birth and BPD while controlling for
diﬀerences in population demographic characteristics, post-
natal diagnosis, and respiratory management variables dur-
ing the first seven days of life. With the final sample of cases
and controls, the power calculation for the research hypo-
thesis tested was 82%, according to the following parameters:
incidence of BPD 30%, type I error probability of 0.05, and
expected size eﬀect (odds ratio, OR) of 2.0. Results of all
multivariate analyses are expressed as odds ratios (ORs) with
their corresponding 95% CI. All analyses were carried out
using the SAS program (SAS Institute, Cary, NC).
3. Results
A total of 216 (77.42%) infants survived to 36wPMA, and
four were excluded from the analysis due to missing data or
because they did not meet the case or control definitions.
The final analysis included 212 infants; 64 (30%) met the
definition of BPD.
3.1. Identification of Risk Factors for BPD in the Whole
Population. Mean GA and birth weight were lower in the
BPD group (Table 1); no diﬀerences were observed in other
perinatal characteristics between cases and controls. Tables 2
and 3 present the results of bivariate analysis controlling
for GA at birth. Use of rescue surfactant, no surfactant
exposure, diagnosis of PDA, chorioamnionitis, and confirmed
or suspected PPROM were variables independently associated
to BPD.
Following a stepwise forward approach, the initial logis-
tics model showed that PPROM, nCPAP + MV, no surfactant
exposure,rescue surfactant, PDA, median daily FIO2 (sub
index is not allowed in this website), and sepsis were asso-
ciated with a higher risk of BPD. When city of birth was
introduced into the model as a control variable, we observed
that median daily FIO2 and PDA lost statistical significance,
suggesting the presence of an interaction. We conducted a
series of multivariate models testing for interactions between
the variables: city of birth, median daily FIO2; sepsis and PDA.
The only significant interaction observed was between the
variables “Bogota´ as city of birth” and “median daily FIO2”
The results of the final logistic regression model controlling
this interaction are showed in Table 4. “Bogota´ as city of
birth” was the most significant independent variable asso-
ciated with BPD; other variables associated with BPD in the
initial model remained significantly associated (Table 4).
3.2. BPDRates and City-Specific Diﬀerences. The distribution
of maternal and infant perinatal characteristics, infant post-
natal diagnosis, and respiratory management practices in the
first seven days of the infants’ life was similar in all cities
(Table 5); however, there are statistically significant diﬀer-
ences between cases and controls among cities.
The proportion of BPD cases in infants whose mothers
received antenatal steroids was significantly higher in Bogota´
than in any other city. In Bucaramanga, infants with BPD had
lower birth weights than infants in Cali or Bogota´. Infants
born in Bogota´ that required MV after nCPAP (nCPAP +
MV) and those treated with rescue surfactant or no surfactant
exposure had a higher incidence of BPD compared to infants
of similar characteristics born in Cali or Bucaramanga.
Infants born in Bogota´ had higher median values of daily
FIO2 compared to Bucaramanga and Cali, and infants diag-
nosed with BPD in Bogota´ received higher concentrations of
daily supplemental oxygen than controls, while BPD cases in
Cali and Bucaramanga did not.
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Table 2: Distribution of maternal characteristics by BPD status.
Characteristics
All infants
BPD
Cases Controls
P OR∗ 95% CI
n = 212 n = 64 n = 148
Maternal characteristics
Mean age, n (%)
<18 years 15 (7.1) 5 (7.8) 10 (6.8) 1.08 0.38 3.08
18–35 years 173 (81.6) 52 (81.3) 121 (81.8) 0.959 1.00
>35 years 24 (11.3) 7 (10.9) 17 (11.5) 0.97 0.50 1.88
Type of delivery, n (%)
Vaginal 35 (16.5) 12 (18.8) 23 (15.5)
0.563
1.00
Cesarean 177 (83.5) 52 (81.3) 125 (84.5) 0.86 0.51 1.43
Multiple gestation n (%) 22 (10.4) 6 (9.4) 16 (10.8) 0.753 0.89 0.44 1.83
Antenatal steroids, n (%) 184 (86.8) 56 (87.5) 128 (86.5) 0.072 1.32 0.63 2.75
PPROM, n (%) 76 (35.8) 30 (46.9) 46 (31.2) 0.028 1.58 1.06 2.36
Duration of rupture of membranes, n (%)
<24 h 35 (46.1) 12 (40.0) 23 (50.0)
0.275
1.00
24–48 h 14 (18.4) 5 (16.7) 9 (19.6) 0.76 0.14 4.02
48–72 h 8 (10.5) 2 (6.7) 6 (13.0) 1.76 0.52 5.94
>72 h 19 (25.0) 11 (36.7) 8 (17.4) 1.04 0.45 2.41
Chorio confirmed, n (%) 11 (5.2) 4 (6.5) 7 (4.7) 0.647 1.22 0.54 2.74
Chorio confirmed or suspected, n (%) 39 (18.4) 17 (26.6) 22 (14.9) 0.044 1.60 1.04 2.47
Chorio: chorioamnionitis, PPROM: preterm premature rupture of membranes.
In relation to postnatal diagnosis during the first 7 days
of life, the diagnosis of PDA was higher in Bucaramanga,
but the largest proportion of BPD cases in infants with PDA
was observed in Bogota´. The diagnosis of sepsis was also
more frequent in Bucaramanga and Cali, but the largest
proportion of BPD cases among infected infants was seen in
Bogota´, followed by Cali and Bucaramanga (P < 0.0001).
Bivariate analysis stratified by city of birth (Table 5)
showed the following: for infants born in Bogota´, the diag-
nosis of sepsis in the first seven days of life and the incremen-
tal levels of daily median FIO2 as variables mainly associated
with a higher risk of BPD; for infants born in Cali, air leak
syndrome, PPROM, and PDA in the first seven days of life
were the variables associated with BPD, while in Bucara-
manga PPROM was the only significant risk factor associated
with BPD.
To explore for associations between city of birth and BPD,
we generated a logistics model controlling potential con-
founders. Multivariate results are shown in Table 6; Bogota´
as city of birth was strongly associated with an increased
risk of developing BPD (OR 1.82 95%CI 1.31–2.53). Other
variables in the model associated with a higher risk of BPD
were rescue surfactant, no surfactant exposure, nCPAP + MV,
median daily FIO2, PDA, and sepsis.
4. Discussion
In this study population, the incidence of BPDwas 30%. This
rate is higher than the average rates reported in populations
with similar gestational ages in developed countries [1, 2, 5–
7]. Our results showed that infants born in Bogota´ had
nearly twice the risk of developing BPD than infants born
in Bucaramanga or Cali, independently of diﬀerences in
maternal, infant, and therapeutic risk factors. Additionally,
Bogota´ showed the highest rates of BPD cases associated with
the presence of air leak syndrome, exposure to MV, rescue
surfactant or no surfactant exposure, PDA, and sepsis, when
compared to other cities. It also had the highest values of
daily supplemental oxygen to reach the target SaO2 among
all the cities. Exposure to antenatal steroids did not appear to
protect infants born in Bogota´ from developing BPD.
Because Bogota´ is located a higher altitude (more than
2600masl) than Bucaramanga and Cali, these results could
suggest that altitudemay play an important role in the patho-
genesis of BPD in Colombia. There are few publications on
altitude-related disease and pulmonary hemodynamics in
pediatric populations, and the altitude where an infant is
born has not clearly been proven to be associated with the
development of BPD. The eﬀect of living at high altitudes
(>2500masl) on lung diﬀusion capacity and pulmonary
hemodynamics has been described in highland children [28].
As a result of the low partial pressure of oxygen in the
environment, oxygen uptake into the lungs is enhanced by
increases in minute ventilation, lung compliance, and pul-
monary diﬀusion. The decreased partial pressure of oxygen
in the lungs of highland children has also been associated
with higher pulmonary artery pressures [28–31]. Several
investigators have also found that functional closure of
ISRN Pediatrics 5
Table 3: Distribution of infant characteristics by BPD status.
Characteristics All infants
BPD
Cases Controls
n = 64 n = 48 P OR∗ 95% CI
Sex, n (%)
Male 108 (50.9) 34 (53.1) 74 (50.0)
0.676
1.10 0.73 1.66
Female 104 (49.1) 30 (46.9) 74 (50.0) 1.00
Gestational age, n (%)
27–29 weeks 114 (53.8) 40 (62.5) 74 (50.0)
0.094
1.43 0.93 2.20
30-31 weeks 98 (46.2) 24 (37.5) 74 (50.0) 1.00
Birth weight, n (%)
<1000 g 37 (17.4) 14 (21.9) 23 (15.5)
0.301
1.70 0.86 3.38
1000–1500 g 130 (61.3) 40 (62.5) 90 (60.8) 1.30 0.76 2.53
>1500 g 45 (21.2) 10 (15.6) 35 (23.6) 1.00
SGA n (%) 12 (5.7) 3 (4.7) 9 (6.1) 0.687 0.82 0.30 2.23
Apgar score <5 at 5min, n (%) 2 (0.94) 0 (0.0) 2 (1.35) 0.350 1.00 0.82 1.21
Mean SNAP II, n (%)
0 to 10 143 (67.4) 102 (68.9) 41 (64.0)
11 to 19 54 (5.5) 36 (24.3) 18 (28.1) 0.381
>20 15 (7.1) 10 (6.8) 5 (7.2)
PDA (%) 64 (30.2) 30 (46.9) 34 (23.0) 0.001 2.04 1.38 3.03
Air Leak Syndrome (%) 12 (5.7) 6 (9.4) 6 (4.0) 0.124 1.72 0.94 3.16
Sepsis (%) 109 (51.4) 39 (60.9) 70 (47.3) 0.068 1.47 0.98 2.38
IVH grade III or IV (%) 4 (1.90) 1 (1.6) 3 (2.0) 0.820 0.83 0.15 4.56
Ventilatory Support (%)
nCPAP only 162 (76.4) 37 (57.8) 125 (84.5) 0.000 1
nCPAP + MV 50 (23.6) 27 (42.2) 23 (15.5) 2.36 1.61 3.46
LOMV ≥ 7 days (%)∗ 15 (30.0)∗ 8 (29.6) 7 (30.4) 1.12 0.68 1.84
Use of Surfactant (%)
Very early 106 (50.0) 20 (31.2) 86 (58.1) 0.000 1
Rescue 27 (12.7) 18 (28.1) 9 (6.1) 6.16 2.53 15.02
No surfactant 79 (37.3) 26 (40.6) 53 (35.8) 3.53 2.19 5.69
FIO2 (median values) 0.53 0.52 0.52 0.102
Deaths before 36wPMA are excluded. BPD: bronchopulmonary dysplasia, SGA: small for gestational age, SNAP-II: score for neonatal acute physiology,
nCPAP: nasal continuous positive airway pressure, MV: mechanical ventilation, LOMV: length of mechanical ventilation, PDA: patent ductus arteriosus.
Table 4: Multivariate analysis predicting BPD for the entire cohort
controlled by city of birth N = 212.
Variables OR 95% CI
Preterm premature rupture of membranes 1.17 1.05 1.31
Ventilatory support (nCPAP +MV) 1.18 1.01 1.38
Use of surfactant (rescue) 1.63 1.28 2.08
Use of surfactant (no surfactant) 1.37 1.12 1.67
City of birth (Bogota´)1 1.9 1.46 2.49
FIO2
1 (median value) 1.58 1.11 2.26
PDA 1.14 1.01 1.28
Sepsis 1.12 1.01 1.26
1
OR adjusted by interaction term between Bogota and FIO2.
the ductus arteriosus in the newborn is delayed at high
altitudes as a consequence of increased pulmonary vascular
pressures [32–35]. The transition from oxygenation via the
placenta to oxygenation across the formerly fluid-filled lungs
is especially precarious in a low-oxygen environment [36];
with the onset of ventilation immediately after birth, the
oxygen tension in the alveolus and pulmonary capillaries of
neonates may not increase as expected, resulting in postnatal
persistence of fetal circulation [36]. In the absence of pul-
monary disorders, normal neonates may experience frequent
episodes of arterial oxygen desaturations and hypoxia during
the first week of life. Studies comparing healthy infants born
at high altitudes (>3100masl) with infants born at sea level
have shown that a week after birth the SaO2 of high-altitude
infants declines, whereas SaO2 gradually rises after birth or
remains constant over time in infants born at sea level [32].
As a result of these events, it is possible that premature infants
born at high altitudes have a prolonged transition period
and early dependency on high concentrations of oxygen and
ventilatory support compared to their counterparts born at
lower altitudes. The presence of RDS would enhance ven-
tilation perfusionmismatch leading to more hypoxia, oxygen
dependency, oxidative stress, and higher levels of ventilatory
support, increasing the risk and severity of BPD. It is also
possible that the observed dependency on supplemental
oxygen in our population of premature infants is the result
of physiological oxygen dependency and not BPD. This may
6 ISRN Pediatrics
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Table 6: Multivariate analysis exploring associations between BPD
and city of birth (n = 208).
OR 95% CI
City of birth (Bogota´)1 1.82 1.31 2.53
City of birth (Cali) 0.80 0.46 1.39
Gender (male) 1.04 0.93 1.15
Gestational age (wPMA) 1.02 0.97 1.07
Birth weight 1.00 1.00 1.00
Antenatal steroids 1.00 0.84 1.18
Preterm premature rupture of membranes 1.18 1.05 1.33
Ventilatory support (nCPAP+MV) 1.15 1.02 1.38
Use of Surfactant (rescue) 1.36 1.10 1.68
Use of Surfactant (no surfactant) 1.19 1.06 1.33
FIO2 (median value)1 1.54 1.10 2.16
Air Leak syndrome 0.96 0.75 1.24
PDA 1.13 1.00 1.29
Sepsis 1.14 1.01 1.29
1
OR adjusted by interaction term City × FIO2 (Lincom statistics). nCPAP:
nasal continuous airway pressure, MV: mechanical ventilation, PDA: patent
ductus arteriousus.
be due to the fact that the definition used for BPD does not
take into account clinical or radiographic changes.
The association between PDA and BPD has previously
been documented [4, 12, 37]. It is also possible that the pro-
longed closure of the PDAmay play a role in the pathogenesis
of BPD, especially as the pulmonary vascular resistance
begins to drop, but we cannot answer this question because
we did not assess the duration of the PDA, the presence
of pulmonary hypertension, or the presence of pulmonary
edema or hemorrhage in this population of infants. Likewise,
we did not assess the eﬀect of fluid intake on the development
of PDA and BPD because this information was not collected
in the initial trial [7, 14, 37, 38]. Previous studies have
demonstrated the relationship between the presence of late-
onset sepsis, PDA, and the development of BPD [12, 37]. Our
study suggests that altitude enhances their negative eﬀects
and other traditional risk factors associated with BPD [38].
In our population, PPROM was found to be a significant risk
factor for BPD while chorioamnionitis was not. This finding
could be explained in part because amniocentesis and amni-
otic culture fluids were not taken routinely in all participa-
ting centers as part of the workup for suspected chorioam-
nionitis in mothers with preterm labor or premature rupture
of membranes. The association of BPD with preterm labor
and PPROM has been well documented in the medical
literature [39].
Finally, our study emphasizes the need to minimize MV
exposure and oﬀer surfactant replacement therapy within the
first hour of life to infants with RDS on NCPAP in order to
decrease the incidence of BPD in this population [20, 40, 41].
To summarize, this study suggests that altitude may be an
important risk factor associated with increased supplemental
oxygen dependency and the development of BPD. Future
studies need to determine whether altitude plays a role in
the pathophysiology of BPD or if it is just a marker for
physiologic oxygen demands. They also need to use a more
accurate definition for BPD, measuring not only the need of
supplemental oxygen but also the radiographic findings and
clinical signs.
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